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Summary Zonisamide safety was evaluated based on a postmarketing surveillance
study of patients treated for 1—3 years. Nine hundred twenty-eight children and 584
adults (ages 1 month to 79 years), including 372 newly-diagnosed patients, received
zonisamide for partial and generalized epilepsies. Of the intractable patients, 1088
received zonisamide in combination with other antiepileptic drugs (AED), and 52
successfully transitioned to zonisamide monotherapy. A total of 1089 adverse events
occurred in 476 (31.5%) of 1512 patients. Incidence of adverse effects was signifi-
cantly lower among patients receiving zonisamide monotherapy than in those receiv-
ing polytherapy: 21% (18.9% of children, 29.4% of adults) versus 35.6% (30.4% of
children, 41.7% of adults), respectively. The total incidence of adverse effects was
lower for children (26.2%) than for adults (39.9%). Most common adverse events
included mental/psychiatric symptoms (19.4%), gastrointestinal symptoms (8.7%),
and neurological symptoms (6.5%). Effects that seemed unique to zonisamide were
impairment of mental function, motivation or volition, and hypohidrosis. Urinary
calculi were detected in only two patients (0.13%). Teratogenicity was evaluated in six
patients. Two patients on zonisamide monotherapy and three on polytherapy deliv-
ered normal children. One of four patients on polytherapy conceived a fetus with a
skull defect with cerebral and cerebellar dysgenesis, namely anencephaly.
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Zonisamide has been proven to be a useful antiepi-
leptic drug (AED) with a broad therapeutic spec-
trum.1—5 It has shown efficacy for intractable
epilepsies, including frontal lobe epilepsy, West
and Lennox-Gastaut syndromes, and severe myoclo-
nic epilepsy in infancy.6,7 The safety of zonisamide,
including adverse effects and teratogenicity, was
examined in a postmarketing prospective follow-up
survey of Japanese patients treated for 1—3 years
with zonisamide, either as monotherapy or as a
component of polytherapy.. Published by Elsevier Ltd. All rights reserved.
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Table 1 Adverse effects of zonisamide
Classification of
adverse effects
Monotherapy (424), no. (%) Polytherapy (1088), no. (%) Total (1512 patients),
no. (%)Children (339) Adults (85) Children (589) Adults (499)
Mental/psychiatric 46 (13.6) 12 (14.1) 122 (20.7) ** 113 (22.6) 293 (19.4) ***
Neurological/visual 5 (1.5) 4 (4.7) 24 (4.1) * 65 (13.0)*,### 98 (6.5)***,###
General condition 5 (1.5) 3 (3.5) 30 (5.1) ** 42 (8.4)# 80 (5.3)***,###
Gastrointestinal 13 (3.8) 8 (9.4)# 43 (7.3) * 68 (13.6)### 132 (8.7)**,###
Dermatologic 2 (0.6) 3 (3.5)# 17 (2.9) * 11 (2.2) 33 (2.2)
Cardiorespiratory 1 (0.3) 4 (0.8)# 5 (0.3)
Urologic 3 (0.9) 1 (1.2) 4 (0.7) 6 (1.2) 14 (0.9)
Fetal (teratogenicity) 1 (0.2) 1 (0.1)
Hepatic 4 (1.2) 1 (1.2) 12 (2.0) 19 (3.8) 36 (2.4)#
Hematological 2 (0.6) 5 (0.8) 7 (1.4) 14 (0.9)
Metabolic 2 (0.6) 1 (1.2) 9 (1.5) 7 (1.4) 19 (1.3)
Total cases with
adverse effects
64 (18.9) 25 (29.4)# 179 (30.4) *** 208 (41.7)*,### 476 (31.5)***,###
Note: significant difference between monotherapy and polytherapy (*P < 0.05, **P < 0.01, ***P < 0.001). Significant difference
between children and adults (#P < 0.05, ##P < 0.01, ###P < 0.001).Methods
Twenty-three groups of clinical epileptologists and
two independent clinicians registered 1793 patients
having active partial and generalized epilepsy who
had had no previous zonisamide therapy. Data on
clinical seizure symptoms and frequency, general
conditions, electroencephalogram (EEG), and
laboratory test results were collected prior to zoni-
samide treatment. Physicians performed regular
follow-up examinations for up to 3 years.
Of registered patients, 1512 were included in the
safety analysis: 928 children who ranged from 1
month to 15 years of age, and 584 adult epilepsy
patients ages 16—79 years. Three hundred seventy-
two patients were newly treated with zonisamide
alone, 52 others were successfully switched to
monotherapy, and 1088 received polytherapy that
included zonisamide. Of the total, 1044 patients had
partial epilepsy, 458 had generalized epilepsy, and
10 had other epilepsies or were unclassifiable.
Among these 1512 patients, 885 were treated with
zonisamide for at least 1 year and 493 received
zonisamide for 2 or more years.
Adverse events were based on clinician reports
and included events with and without causal rela-
tionships to zonisamide (Table 1).Figure 1 Incidence of adverse effects: children vs.
adults.Results
Incidence of adverse effects
One thousand eighty-nine adverse events were
reported by 476 (31.5%) of 1512 patients. Childrenhad a significantly lower incidence of adverse effects
than adults, 26.2% (243/928 cases) versus 39.9%
(233/584 cases) (P < 0.001), respectively, (Fig. 1).
The rate of adverse effects was significantly lower in
patients treated with zonisamide monotherapy than
polytherapy: 21.0% (89/424cases) versus 35.6% (387/
1088 cases) (P < 0.001), respectively, (Table 1). The
incidencewasalso significantly lower in children than
adults in both monotherapy and polytherapy: 18.9%
versus 29.4% (P < 0.05), and 30.4% versus 41.7%
(P < 0.001), respectively (Fig. 1).
Classification of adverse effects
General trends
The most frequently observed adverse effects
occurred in the central nervous system (CNS), with
mental/psychiatric symptoms reported for 293
patients (19.4%) and neurological/visual symptoms
for 98 patients (6.5%). Although mental symptoms
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and adults, the rate was higher in the polytherapy
group (21.6%; 20.7% of children and 22.6% of
adults) than in the monotherapy group (13.7%;
13.6% of children and 14.1% of adults) (P < 0.001)
(Table 1).
Ninety-five adverse events of general condition
were reported in 80 patients (5.3%). These included
weight loss in 42 patients (2.8%), malaise in 27
(1.8%), weakness in 14 (0.9%), and fever in 9
(0.6%). Adverse effects in the urinary, cardiovascu-
lar, and respiratory systems were rarely observed.
Hepatic adverse effects, 85 events in 36 patients,
involved liver enzyme activities, including increased
aspartate aminotransferase, alanine aminotransfer-
ase, or g-glutamyl transpeptidase.
Mental and psychiatric symptoms
The main symptom was sleepiness, which was noted
in 246 patients (16.3%). Although it was higher in the
polytherapy group (18.0%) (P < 0.01), the rate was
high in the monotherapy group as well (11.8%).
Specific symptoms included enervation in
43 patients (2.8%), loss of spontaneity in 41
(2.7%), decreased mental activity in 36 (2.4%),
irritable or excitable behavior disorders in 45
(3.0%), psychotic symptoms in 13 (0.9%) (including
depression in 8 [0.5%]), hallucination or delusion
in 12 (0.8%), and anxiety or hypochondria in 14
(0.9%) (Table 2). These adverse effects were notTable 2 Neurological and mental/psychiatric adverse effe
Neurological/mental
symptoms
Monotherapy (424), no. (%
Children (339) Adults (85
Ataxia, dysequilibrium
Vertigo, dizziness 1 (1.2)
Diplopia
Paresthesia
Dyslalia
Tremor, involuntary movement 1 (0.3) 1 (1.2)
Headache 5 (1.5) 3 (3.5)
Seizure aggravation
Disturbed consciousness
Sleep disorder, insomnia 1 (0.3) 1 (1.2)
Sleepiness 41 (12.1) 9 (10.6)
Enervation, decreased volition 7 (2.1) 3 (3.5)
Hypomnesia 2 (0.6) 1 (1.2)
Decreased mental activity 4 (1.2) 2 (2.4)
Irritability, excitability 5 (1.5) 5 (5.9)#
Anxiety, hypochondria 1 (1.2)
Psychotic/depressive state 1 (0.3) 3 (3.5)##
Delusion, hallucination 1 (1.2)
Note: significant difference between monotherapy and polythera
between children and adults (#P < 0.05, ##P < 0.01, ###P < 0.001).always dose-related, but often appeared within
therapeutic serum levels. Overall, the number
of patients reporting psychiatric symptoms was
small.
Neurological adverse effects
Neurological symptoms were observed in 98
patients (6.5%). These included ataxia or dysequi-
librium in 50 patients (3.3%), vertigo or dizziness in
16 (1.1%), diplopia in 17 (1.1%), and dyslalia in 9
(0.6%). These effects were rarely observed in the
patients receiving zonisamide monotherapy, but
occurred significantly more often in those with
polytherapy (P < 0.001). The strong influence of
combined AEDs was suggested as the reason for
these adverse effects.
Tremor/involuntary movement (11 patients,
0.7%) and headache (29 patients, 1.9%) were
observed in both mono- and polytherapy groups,
indicating a possible causal relationship to the basic
illness or epilepsy itself. The aggravation of seizures
or induction of new seizures or microseizures8
occurred in three patients (0.2%).
Dermatologic adverse effects
Skin rash was observed in 21 patients (1.4%) and
itching in 8 (0.5%). Hypohidrosis was observed in 14
patients (0.9%), predominantly children receiving
polytherapy, and was often accompanied by fever,
usually in summer.cts
) Polytherapy (1088), no. (%) Total (1512 patients),
no. (%)) Children (589) Adults (499)
18 (3.1) ** 32 (6.4)*,## 50 (3.3)***,###
15 (3.0)### 16 (1.1)###
1 (0.2) 16 (3.2)### 17 (1.1)**,###
1 (0.2) 2 (0.4) 3 (0.2)
6 (1.0) 3 (0.6) 9 (0.6)
4 (0.7) 5 (1.0) 11 (0.7)
5 (0.8) 16 (3.2)### 29 (1.9)##
2 (0.3) 1 (0.2) 3 (0.2)
2 (0.4) 2 (0.1)
3 (0.5) 8 (1.6) 13 (0.9)#
101 (17.1) * 95 (19.0) 246 (16.3) **
53 (9.0) *** 21 (4.2)### 84 (5.6) ***
3 (0.5) 5 (1.0) 11 (0.7)
15 (2.5) 15 (3.0) 36 (2.4)
17 (2.9) 18 (3.6) 45 (3.0)
6 (1.0) 7 (1.4) 14 (0.9)
4 (0.7) 5 (1.0) 13 (0.9)
1 (0.2) 10 (2.0)### 12 (0.8)###
py (*P < 0.05, **P < 0.01, ***P < 0.001). Significant difference
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Gastrointestinal symptoms, noted in 132 patients
(8.7%), included anorexia in 99 (6.5%), nausea in 33
(2.2%), vomiting in 20 (1.3%), and abdominal pain in
9 (0.6%). Anorexia was observed significantly more
often in patients treated with polytherapy, 87 (8.0%)
(P < 0.001), but was also noted in 12 patients (2.8%)
receiving zonisamide monotherapy.
Urologic adverse effects
Urologic symptoms, occurring in 14 patients (0.9%),
included four patients (0.3%) each experiencing
urinary incontinence and enuresis, and three
(0.2%) with hematuria. Urolithiasis was suspected
in two adult male patients (0.1%), one of whom had
a past history of urinary tract calculi 15 years earlier.
Teratogenicity
Six women in the study were treated with zonisa-
mide during pregnancy. Two patients on monother-
apy delivered healthy children. Out of four patients
on polytherapy, a fetal malformation of skull defect
with cerebral and cerebellar hypogenesis, namely
anencephaly, was reported in one patient receiving
zonisamide in combination with phenytoin. The
other three patients delivered normal children.
Severity of adverse events
According to a subjective severity evaluation by
each epileptologist, the 1089 adverse events occur-
ring in 476 of 1512 patients were classified as fol-
lows: 602 mild events (55.3%), 416 of moderate
severity (38.2%), and 58 severe events (5.3%).
Severity was not reported in 13 events.
Severe adverse events included seizure aggrava-
tion (including induced microseizures8), hypohidro-
sis, anorexia and weight loss, andmental symptoms,
such as decreased spontaneity or depressed mental
activity, psychotic state, and irritability.
Seizure aggravation and idiosyncratic adverse
effects, such as skin rash, fever, and agranulocyto-
sis, appeared relatively early and with low doses
of zonisamide. Mental symptoms, anorexia, and
weight loss, however, varied greatly in time of
appearance and the dosage at which they occurred.
Zonisamide was discontinued in 55.2% of the
patients with severe adverse events.
Adverse effects observed with long-term
use
Of the 1512 total patients, 864 were treated with
zonisamide for more than 1 year. Eight hundred
eighty-one adverse events were experienced by
433 of 1512 study participants (28.6%) within thefirst year of zonisamide treatment; 208 events
occurred in 120 of 864 patients (13.9%) in the second
year or later. Late-appearing adverse effects
included one case each of bowel incontinence,
palpitation, micturition disorder, muscle weakness,
increased lactate dehydrogenase, decreased
immunoglobulin A (IgA), and increased blood urea
nitrogen. Severe adverse effects observed in the
second year or later included two cases of psychotic
state, and one case each of auditory hallucination,
anorexia, weight loss, nausea, and vomiting.
Laboratory data showed that g-glutamyl trans-
peptidase abnormalities were significantly higher in
the second year than the first year: 17 out of 588
cases (2.89%) versus 14 out of 1011 cases (1.38%)
(P = 0.05), respectively.
Factors related to incidence of adverse
effects
Sex
Sex difference had no influence on the incidence of
adverse effects.
Age
One factor clearly related to the appearance of
adverse effects is age, with adverse effects occur-
ring less frequently among children than among
adults. Specifically, adverse effects were experi-
enced by 24.1% (164/680) of children younger than
12 years of age, without significant difference
among subdivided age groups, and gradually
increased in incidence up to age 50 years: 31.8%
(79/248) of patients ages 12—15; 38.4% (53/138) in
ages 16—19; 41.2% (77/187) in ages 20—29; 42.1%
(53/126) in ages 30—39; and 43.9% (29/66) in ages
40—49. However, this trend started to reverse
among patients 50 years and older: 33.3% (16/48)
of patients ages 50—59 experienced adverse effects;
30.8% (4/13) of patients ages 60—64; and 16.7% (1/
6) of those 65 and older.
A similar age-related tendency was observed in
monotherapy and polytherapy groups; however,
there was considerable variation in the incidence
of adverse events among age categories in the
monotherapy group, presumably due to the small
number of patients in each category.
Classification of epilepsy
The type of epilepsy had no apparent effect on the
incidence of adverse effects. Among patients on
monotherapy, no difference was seen between par-
tial epilepsy, 72/336 patients (21.4%), and general-
ized epilepsies, 17/88 (19.3%). This was true in the
polytherapy group as well, where no difference
was seen between partial epilepsy cases, 259/708
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Figure 2 Incidence of adverse effects: monotherapy vs.
polytherapy. Note: One additional patient received poly-
therapy, but the number of additional AEDs this patient
received was unavailable.(36.6%), and generalized epilepsy cases, 125/370
(33.8%).
Neurological complications
Neurological abnormalities, such as mental retarda-
tion, motor disturbances, or behavior disorders,
seemed to contribute to a significantly higher inci-
dence of adverse effects; 263/727 (36.2%) versus
213/785 (27.1%) in total patients (P < 0.001). When
subcategorized into monotherapy and polytherapy:
25/92 (27.2%) versus 64/332 (19.3%) patients had
adverse events with monotherapy, and 238/635
(37.5%) versus 149/453 (32.9%) with polytherapy.
The incidence was not statistically significant.
Zonisamide dosage
Rates of adverse effects were inversely related to
doses of zonisamide. Children taking 2 mg/kg per
day or less, and adults taking 100 mg per day or less
of zonisamide showed the highest adverse event
incidence. This tendency corresponds to the finding
that 34.2% of adverse events appeared within the
first month of zonisamide initiation.
Number of combined antiepileptic drugs
When compared to 21.0% (89/424) for the incidence
of adverse effects experienced in monotherapy, a
significant increase was noted when zonisamide was
combined with up to three additional AEDs; an even
greater increase occurred in combinations of four to
five AEDs (P < 0.001). The incidence of adverse
effects was 32.6% (103/316) with one additional
AED, 36.6% (150/410) with two other AEDs, 33.3%
(80/240) with three other AEDs, and 43.8% (53/121)
with additional four to five AEDs (Fig. 2).Discussion
The rate of adverse events (31.5%) found in this
study is lower than the 51.3% (517/1008 cases)
observed in the clinical developmental studies,1
perhaps because the increased proportion of
patients receiving zonisamide monotherapy
(28.0%) experienced a lower rate of adverse effects
than those receiving polytherapy.
Among the common adverse effects involving the
CNS, neurological symptoms, such as ataxia, ver-
tigo, and double vision, were probably toxic effects
elicited in a dose-related manner, as was the case
with other AEDs.
On the other hand, troublesome adverse effects
involving the higher brain function, such as impaired
mental and cognitive activities,9 decreased motiva-
tion or volition, psychiatric symptoms,10—12 and
behavior disorders,13 may have serious effects on
patients’ academic or social lives. Although these
are usually aggravated dose-dependently,9 theymay
appear at relatively low doses10—13 and often result
in the discontinuation of zonisamide. These effects
relating to the higher brain function were suggested
to be specific for zonisamide, considering a rela-
tively high detection rate in patients receiving
monotherapy and improvement by discontinuation
of zonisamide. Some of this aspect may be evalu-
ated by neurophysiological methods, such as event-
related potentials.7
Because 110 of 246 patients (44.7%) with sleepi-
ness reported this complaint during the first month
of administration, this adverse effect may be the
result of a high initial dose and subsequent rapid
dose increase. Administering a low initial dose,
followed by a gradual dose increase may minimize
this effect.
Seizure aggravation or induction of new seizures,
such as induced microseizures,7,8 was reported in
three cases (0.2%). Because all of these occurred
under polytherapy, seizure-inducing effects of zoni-
samide, like those noted with benzodiazepines,
warrant further study.
Hypohidrosis is a peculiar adverse event for zoni-
samide. Its incidence was only 0.9% in this survey,
partly because the study included 584 adults
(38.6%). It may not, however, be a rare adverse
effect in infancy and childhood, as hypohidrosis
was observed in 12 (17.1%) of 70 children with
epilepsy by Okumura et al.14 and 38 (24.8%) of
153 cases by Hosoda et al.15 The decreased sweating
response to acetylcholine loading suggests the func-
tional suppression of sweat glands by zonisamide as
its mechanism.14 Accordingly, a probable dose-
dependent decrease in sweating should be consid-
ered as a cause of fever in infants and severely
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therapy), particularly in summer time.
Urolithiasis had been a problem in trials in the
United States and Europe.1—5 In this series, it was
suspected in two adult male cases (0.1%); however,
the incidence of two men out of 280 male adult
subjects (0.71%) was not higher than the 1.3% rate
in the general Japanese male adult population.16
Notwithstanding, Kubota et al.17 suggested an
increased risk of urolithiasis in patients who are
bedridden and/or receiving zonisamide polytherapy.
Among the gastrointestinal symptoms, loss of
appetite is one of the main characteristics,1,4 some-
times having serious adverse effects. This may occur
with relatively low doses of zonisamide and often
worsens in relationship to dose, leading to consider-
able weight loss that may necessitate a decrease in
dose or discontinuation of zonisamide. Its long
serum half-life of over 50 hours may enable once-
a-day (QD) administration after dinner to minimize
anorexia.
Concerning teratogenicity, of all 26 known births
or pregnancies during the zonisamide pre- and post-
marketing periods, two had malformation (7.7%),
including the aforementioned one fetus with anen-
cephaly. The other child was born with an atrial
septal defect to a women treated with combination
therapy that included phenytoin and valproate.18
The limited number of pregnancies during zoni-
samide treatment18 and the extent of teratogenicity
suggested by animal trials19,20 indicate the need for
further precise clinical investigations on teratogeni-
city. Administration of new drugs to women of child-
bearing age should be carefully considered, and
limited to only when remarkable efficacy is con-
firmed and there is no other alternative treatment.
Factors relating to the appearance of adverse
effects include the age factor–—that is, a lower
incidence in those younger than 12 years and a
higher incidence in those of 20—50 years. Differ-
ences in pharmacokinetics, including drug metabo-
lism and the higher proportion of polytherapy in
adult patients (499/584, 85.4%) than children
(589/928, 63.5%), may provide an explanation.
Classification of epilepsy probably has no direct
relation to adverse effects. Intractable epilepsies,
such as Lennox-Gastaut syndrome and temporal
lobe epilepsy, however, may indirectly relate to
the high incidence of adverse effects, reflecting
the need for polytherapy or high-dose treatment
in such patients. Likewise, neurological abnormal-
ities are often associated with intractable epilep-
sies, requiring polytherapy or high drug doses, which
may explain the high incidence of adverse effects.
It appears this drug’s incidence of adverse events
inversely relates to a lower administration dose.This would indicate the need for a careful initiation
of zonisamide treatment. Moreover, adverse
effects often appear within the first month
after zonisamide induction. Starting with as low a
dose as possible, and gradually increasing the dose
to confirm tolerance, may minimize adverse
effects.Conclusion
Zonisamide is a potent AED with a broad spectrum
of effectiveness for both partial and generalized
epilepsies. However, specific adverse effects, such
as pseudodementia (impaired mental activities),
decreased volition, anorexia, and hypohidrosis,
warrant caution and may restrict its clinical
application.
To increase the usefulness and tolerability, and
reduce associated adverse effects of zonisamide: (1)
monotherapy (or polytherapy with as few additional
AEDs as possible) is recommended. In addition, (2)
the once-a-day administration of zonisamide (up to
the 2—3 mg/kg per day) after the evening meal; (3)
initial doses less than 1 mg/kg per day; and (4)
gradual dose increase up to 5 mg/kg per day and
then to 10 mg/kg per day in small increments over
an extended time interval, may help alleviate the
drowsiness, anorexia, and weight loss associated
with zonisamide therapy.References
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